 Combination will be evaluated in patients with pancreatic ductal adenocarcinoma whose tumors have KRAS and CDKN2A mutations Combination will be evaluated in patients with pancreatic ductal adenocarcinoma whose tumors have KRAS and CDKN2A mutations 